September 2015 | Oncology Business News®

October 19, 2015

Changes in cancer care, regulations, and reimbursement create more pressure on practices than ever before to improve care, reduce costs, and remain viable in an atmosphere of mergers and acquisitions.

September 11, 2015

The experiment with bundled care in oncology is moving forward despite mixed results and lingering concerns about the administrative difficulty of implementation, potential care compromises, and whether innovation can thrive under fixed payments.

September 10, 2015

Some oncologists say they are overwhelmed by the diversity of pathways and payers are too often using them to micromanage decision making.

September 08, 2015

As long as bundles are tied to a desired clinical outcome of relevance to the patients, we can truly move toward value-based medicine and enable the Goldilocks formula of delivery: just the right amount of care, not too much, and not too little-every time.

September 04, 2015

North Shore Hematology Oncology has found a niche for itself by focusing on ways in which it can compete against local giants.

August 31, 2015

Getting ready for ICD-10 has involved a huge commitment to staff training and also much attention to the finer details.

August 28, 2015

New drug candidate necitumumab, which is being reviewed by the FDA as a treatment for patients with locally advanced or metastatic squamous non-small cell lung cancer, received a low cost-effectiveness evaluation in a study published in JAMA Oncology.

August 25, 2015

As cancer drugs soar in price, the National Comprehensive Cancer Network is introducing cost as a measure of the overall value of a therapy, following the trail of ASCO and a doctor from Memorial Sloan Kettering Cancer Center in attempting to put a lid on drug inflation.

August 21, 2015

A huge amount of training and preparation has preceded the October 1 implementation of International Classification of Diseases, Tenth Revision (ICD-10).

August 18, 2015

Costs of radiation treatment for breast, lung, and prostate cancer patients vary greatly based on reasons not connected to patient characteristics.